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HEXADECYLPHOSPHOCHOLINE, A NEW ETHER LIPID ANALOGUE 
Studies on the antineoplastic activity in vitro and in vivo 
C. UNGER, W. DAMENZ, E. A. M. FLEER, D. J. KIM, A. BREISER, P. HILGARD, J. ENGEL, G. NAGEL and H. EIBL 
Abstract 
Hexadecylphosphocholine (He-PC) is a new compound syn- 
thesized according to the minimal structural requirements de- 
ducted from studies with other ether lipids. In vitro studies on 
He-PC revealed remarkable antineoplastic activity on HL60, 
U937, Raji and K562 leukemia cell lines. In addition, He-PC, 
applied orally, showed a superior effect in the treatment of 
dimethylbenzanthracene-induced rat mammary carcinomas when 
compared to intravenously administered cyclophosphamide. Af- 
ter oral application He-PC was well absorbed from the intestine 
and metabolized in the liver by phospholipases C and D. During a 
S-week treatment no hematotoxic effects were detected. In a 
clinical pilot study on breast cancer patients with widespread 
skin involvement, topically applied He-PC showed skin tumor 
regressions without local or systemic side effects. 
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plastic activity. 
Natural ester-lysolecithines (Fig. 1) are known to exist 
in small amounts in biological membranes. Twenty years 
ago, Westphal et al. at the Max-Planck-Institute in Frei- 
burg found that very small amounts of exogenous lysole- 
cithine strongly enhanced the phagocytic activity of pen- 
toned macrophages in vitro and in vivo (1). 
Due to the very short half-life of these ester-lysolecith- 
ines Arnold et al. (2), Eibl et al. (3-5) and Weltzien & 
Westphal (6) synthesized lysolecithine ether analogues 
(Fig. 1) for studies of the macrophage stimulating pro- 
cesses. These compounds are very stable against most 
phospholipid metabolizing enzymes. Surprisingly, these 
alkyllysophospholipids showed strong direct cytolytic ef- 
fects on various tumor cells in vitro and in vivo (7, 8). 
Testing of the structure activity relationship among a 
variety of synthetic alkyllysophosphocholines showed 
that a long alkyl chain and a phosphocholine moiety may 
represent the minimal structural requirement for sufficient 
antineoplastic effects of the ether lipid analogues (9-1 1). 
This finding led to the synthesis of a new compound 
group, the alkylphosphocholines (Fig. 1) (12, 13). 
In the following report, some preclinical and the first 
clinical investigations are presented with hexadecylphos- 
phocholine (He-PC). 
Material and Methods 
Hexadecylphosphocholine was prepared according to 
the general procedures for the conversion of alcohols into 
the respective phosphocholines as described by Eibl & 
Woolley (14), and Eibl & Westphal(4). A Rf-value of 0.20 
for the compound in the system chlorofordmethanollace- 
tic acidwater 100: 60: 20: 5 (by vol.) was observed. Hex- 
adecylph~spho[~H-methyl]choline was obtained by meth- 
ylation of the corresponding hexadecylphosphoethanola- 
mine with ['Hlmethyliodide (15). The resulting specific 
activity of hexadecylphospho['H-methyl]choline was 0.4 
GBq/mmoU. 
Cell experiments. The in vitro cytostatic and cytotoxic 
activities of He-PC were determined in 4 human leukemia 
cell lines: HL60 and U937 (promyelocyte leukemia), Raji 
(Burkitt's lymphoma) and K562 (erythroleukemia). The 
cells were incubated for 72 h at 37°C and 5 % COz in RPMI 
medium with 10% fetal calf serum in different concentra- 
tions of He-PC for up to 72 h. The 50% growth inhibition 
dose (IDSO) after 48 h of incubation was determined by 
calculating the loss of ['Hlthymidine incorporation into 
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cellular DNA. For the half lethal dose (LDso) the trypan 
blue dye exclusion assay was used. 
Animal experiments. The in vivo antineoplastic activity 
of He-PC was determined on dimethylbenzanthracene 
(DMBA)-induced rat mammary carcinomas (16) in com- 
parison to cyclophosphamide as a standard cytotoxic 
agent. Daily oral treatments for 28 days with He-PC or 
with cyclophosphamide as a single i.v. dose respectively, 
were started when DMBA-induced mammary carcinomas 
of adult female Sprague Dawley rats attained a mass of 
To evaluate bone marrow toxicity, the white blood 
count of adult female Sprague Dawley rats was examined 
under oral treatment with He-PC administered in daily 
doses from 4.7 up to 46.4 m a g .  
In organ distribution studies female NMRI mice (25 to 
30 g weight) were used. For this purpose 0.07 MBq He-PC 
(specific activity: 1.85 MBq/pmoIA) was injected into the 
tail vein; oral applications with 0.19 MBq He-PC (specific 
activity: 0.37 MBqlpmoVI) were performed via a tube into 
the stomach. After the indicated time intervals the ani- 
mals were killed, the organs removed, weighed, and the 
amount of radioactivity was determined as described ear- 
lier (17). To evaluate the uptake of He-PC in the various 
organs, the radioactivity was calculated as percentage of 
total dose per gram organ. 
To investigate metabolism of He-PC in the liver, female 
NMRI mice were injected with 1.85 MBq/pmoVI He-PC 
(specific activity: 3.9 MBqpmoIA) into the tail vein. The 
animals were killed after 24 or 72 h respectively. The 
livers were removed and homogenized. Radioactive me- 
tabolites were determined by thin layer chromatography 
as described before (17, 18). 
The first clinical studies on the topical treatment of skin 
metastases with hexadecylphosphocholine were per- 
formed. For better skin penetration He-PC was dissolved 
at a concentration of 20 mg/ml in a composition of water 
and alkylglycerols with different alkyl chain lengths 
(KASKADE, see Table 1). Patients with local recurrence 
of mammary carcinomas were included in the pilot study 
after their written consent. All patients had a history of 
exhaustive treatment including chemotherapy and local 
irradiation. Treatment was performed twice daily on the 
affected skin areas. In order to detect systemic side ef- 
fects, blood and urine analyses, ECG and roentgenologic 
controls were performed. 
0.61.2 g. 
Results and Discussion 
Alkylphosphocholines, a new group of antineoplastic 
agents, are derived from cytotoxic alkyllysophosphocho- 
lines (12, 13). In vitro investigations of He-PC, a com- 
pound representative of alkylphosphocholines revealed 
concentration dependant cytotoxicity and growth inhibi- 
tion shown in Fig. 2 for HL60 cells. IDSO and LDso values 
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Fig. 1. Chemical structure of ester-lysolecithine, etherlysolecith- 
ine, and alkylphosphocholine. 
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Fig. 2. He-PC dose dependant toxicity and inhibition of prolifera- 
tion of the HL60 leukemia cell line. 2x lo5 cells were cultured for 
24, 48 and 72 h in the presence of 2.5 to 40 pglrnl of He-PC; at 
each time point the number of total cells were counted for cell 
growth and the number of dead and alive cells were determined 
for cell vitality by trypan blue dye exclusion. Data represented 
the mean for 3 to 6 independant experiments; SD <+lo%. 
Table 1 
Composition of Kaskade. 20 mg hexadecylphosphocholine was 
dissolved in 1 ml of a formulation composed of water and the 
different alkylglycerols 
Compound % (w/v) 
Nonylglycerol 17 
Prop ylglycerol 33 
H20 33 
Hexylglycerol 17 
incubation (Table 2) when cell growth was in a logarithmic 
phase. The data indicate that HL60 and U937 cells were 
of high sensitivity, Raji of intermediate and K562 of low 
sensitivity against He-PC. The ranking order of suscepti- 
bility of the 4 cell lines was similar in both systems and 
corresponds to results obtained for alkyllysophosphocho- 
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Fig. 3. Antineoplastic activity of He-PC in comparison to cyclo- 
phosphamide on DMBA-induced rat mammary carcinoma. 
Doses: He-PC 31.6 mgkg body weight daily p.0. for 28 days; 
cyclophosphamide: 147 mgkg as a single i.v. injection (maximal- 
ly tolerated dosage). 
end of 
treatment 
Fig. 4. Influence of He-PC treatment on white blood count of 
adult female Sprague-Dawley rats. He-PC w a s  given orally at 
doses of 4.64 (A-A), 14.7 (m-m) and 46.4 (0-0) mgkg per 
day for 35 days. Control (0-0). 
Table 2 
Differeniial sensiiiuity of HL60, U937, Raji and K562 leukemia 
cell lines io He-PC. IDJo values were obiained from ['Hlihymi- 
dine incorporaiion daia after 48 h of incubation; ihe LDm values 
were deiermined from ihe 48-h values as described in Fig. 2 
Cell line He-PC (pdml) 
HL60 5.0 7.7 
u937 3.0 16.0 
Raji 10.0 26.0 
K562 15.0 HO.0 
lines, such as 1-0-octadecyl-2-0-methyl-rac-glycero-3- 
phosphocholine (OM-GPC) in earlier experiments (19). 
The in vivo antitumoral effect of He-PC was studied in 
DMBA-induced rat mammary carcinomas in comparison 
to cyclophosphamide, which is known to be an active 
compound in this tumor model (20). He-PC was given 
Table 3 
Organ distribution of He-PC after oral adminisiraiion in NMRI 
mice. Data represeni perceniage of ioial radioaciiviiylg organ 
(wet weight). SD<20%, 3-10 experiments for  each rime poini. 
For derails see 'Material and Meihods' 
Time l h  5 h  2 4 h  4 8 h  9 6 h  196h 
Blood 0.4 1.8 1.8 1.5 0.9 0.9 
Stomach 7.5 4.4 5.0 3.6 2.6 1.9 
Small int. 17.4 24.5 8.4 4.0 2.8 1.8 
Large int. 0.4 3.3 3.8 2.7 2.0 1.3 
Kidney 2.0 23.0 34.0 26.2 14.5 11.8 
Lung 0.8 8.1 8.3 6.4 4.1 3.0 
Liver 1.3 10.8 14.7 12.4 10.2 5.8 
orally at a dose of 31.6 mg/kg per day over 4 weeks, 
whereas cyclophosphamide was given as a single i.v. 
injection at the maximally tolerated dosage of 147 mg/kg. 
Fig. 3 demonstrates the superior effect of He-PC over 
cyclophosphamide. He-PC resulted in a complete disap- 
pearance of the tumor nodules during the treatment peri- 
od. Within 3 weeks after cessation of the therapy the 
tumors started to regrow. Whether or not this represents 
regrowth of suppressed or development of new tumors is 
currently under investigation. 
He-PC treatment was well tolerated and no overt toxic 
symptoms were noted; in particular no weight loss could 
be observed in the animals. Recently, high therapeutic 
activity of He-PC was also reported for the methylnitro- 
sourea-induced rat mammary carcinomas, whereas 2 
transplantable mammary carcinomas and authochthonous 
benzopyrene-induced sarcomas in the rat exhibited low- 
grade sensitivity to He-PC (21). It is noteworthy that in 
contrast to most cytostatics, He-PC treatment did not 
result in any suppression of the white blood count (Fig. 4). 
The leukocyte count, expressed as percentage of normal 
values, remained unchanged up to a dose of 14.7 mglkg 
per day when given orally, whereas the highly effective 
dose of 46.4 m a g  per day showed a surprising increase 
in leukocyte count during the treatment period. After 
finishing the treatment, the leukocyte count decreased to 
normal values within one week. Since bone marrow ex- 
amination did not show augmentation of granulocyte pre- 
cursor cells (22), it seems likely that an activation of the 
marginal leukocyte pool in the periphery may be responsi- 
ble for this increase in leukocyte count. 
Biodistribution studies after oral administration of He- 
PC in mice clearly demonstrated high absorption rates 
from the intestine (17), permitting oral administration in 
treatment regimens. This finding is in line with other re- 
ports showing that OM-GPC (23) and l-hexadecylmercap- 
to-2-methoxyrnethyl-rac-glycero-3-phosphocholine (24) 
are well absorbed from the intestinal tract. As is also 
known for OM-GPC (231, the highest accumulation of 
He-PC was found to occur in liver, kidney and lungs 
(Table 3). 
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METABOLISM OF k-PC IN MOUSE UVER 
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Fig. 5. Metabolism of hexadecylphospho[3H-methyl]choline in 
mouse liver after i.v. administration. See ‘Material and Methods’ 
for details. Data represent the mean values of 2 experiment for 
the indicated times. 
Metabolism of He-PC was investigated in the mouse 
liver. After oral administration of hexadecylphospho [3H- 
methyllcholine, a time dependant formation of radiola- 
belled choline, phosphocholine and 1,2-diacylglycerophos- 
phocholine was observed (Fig. 5) ,  which suggests the 
importance of phospholipases C and D in He-PC catabo- 
lism. Studies on hydrolysis of He-PC in vitro, carried out 
with phospholipase C (bacillus cereus) and phospholipase 
D (partially purified from cabbage) support the finding that 
He-PC is a substrate for these enzymes (9,ll). Formation of 
1,2-diacylglycerophosphocholine, labelled in the polar 
head group, is consistent with earlier results obtained with 
OM-GPC (15, 18). In the latter study it was shown that the 
labelled phosphocholine group was transferred from OM- 
GPC into 1,2-diacylglycerol, which resulted in the forma- 
tion of phosphatidylcholine. 
The favorable results obtained on tumor response in 
chemically induced autochthonous rat mammary carcino- 
mas prompted us to investigate the antitumoral effect of 
He-PC in the topical treatment of skin metastases in hu- 
mans. For this purpose He-PC was dissolved in short 
chain alkylglycerols (Table l),  since it was recently dem- 
onstrated that these compounds are able to increase drug 
penetration through biological membranes (25, 26). 
Hence, it is possible that these compounds also improve 
penetration of He-PC into the deeper compartments of the 
skin. In addition, hexyl- and nonylglycerol display consid- 
erable growth inhibition properties on leukemia cells in 
vitro (to be published). 
In the clinical pilot study 14 patients with local recur- 
rence of breast carcinoma were included and treated twice 
daily by topical application. The treatment was well toler- 
ated and apart from minor side effects, such as reddening, 
flaking and itching, no systemic toxicity was observed. 
Two patients showed a complete remission lasting 4 and 6 
months, and one patient showed a partial remission for 7 
months. Skin biopsies taken from invaded and normal 
skin after treatment revealed a moderate increase in the 
formation of collagen fibers without affecting the normal 
skin architecture. 
Therefore, topically applied ether lipids may represent a 
safe and effective treatment of skin metastases. Based on 
these promising observations, regular phase I trial studies 
(oral and topical applications) have been started. 
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